A Phase 1 interventional study of MK-6194 and Placebo in Dermatitis, Atopic, sponsored by Merck Sharp & Dohme LLC. Completed at 19 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 302nd largest by enrollment of the 544 interventional ones that give a count, is one of 45 that started in 2022, is one of 82 in phase 1, and was the 469th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 45 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 2 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
43 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 43 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants are randomized to low dose MK-6194 or placebo, administered every 2 weeks (q2w).
Biological: MK-6194 · Biological: Placebo
Participants are randomized to medium dose MK-6194 or placebo administered q2w.
Biological: MK-6194 · Biological: Placebo
Participants are randomized to high dose MK-6194 or placebo administered q2w.
Biological: MK-6194 · Biological: Placebo
Participants are randomized to medium dose MK-6194 or placebo administered q2w.
Biological: MK-6194 · Biological: Placebo
Participants are randomized to a dose less than or equal to high dose MK-6194 or placebo administered q2w.
Biological: MK-6194 · Biological: Placebo
Participants are randomized to a dose less than or equal to high dose MK-6194 or placebo q2w.
Biological: MK-6194 · Biological: Placebo
MK-6194 administered subcutaneously (SC)
Placebo comparator to MK-6194 administered SC
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is presented.
Time frame: Up to approximately 169 days
Number of Participants Who Discontinue Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study intervention due to an AE is presented.
Time frame: Up to approximately 85 days
Area Under the Curve (AUC) From Days 1-15 (AUC1-15) of MK-6194
Blood samples were collected at pre-specified time points to determine the AUC1-15 of MK-6194 in plasma.
Time frame: Day 1 (Predose and 12 hours postdose), Day 8, and Day 15
AUC From Days 29-43 (AUC29-43) of MK-6194
Blood samples were collected at pre-specified time points to determine the AUC29-43 of MK-6194 in plasma.
Time frame: Day 29 (Predose and 12 hours postdose), Day 36, and Day 43
Peak Serum Concentration (Cmax) of MK-6194 (Day 1 to 29)
Blood samples were collected at pre-specified time points to determine the Cmax of MK-6194 in plasma.
Time frame: Day 1 (Predose and 12 hours postdose), Day 8, Day 15, and Day 29 (Predose and 12 hours postdose)
Minimum Serum Concentration (Ctrough) of MK-6194 (Day 1 to 29)
Blood samples were collected at pre-specified time points to determine the Ctrough of MK-6194 in plasma.
Time frame: Predose on Days 15 and 29
Time to Peak Serum Concentration (Tmax) of MK-6194 (Day 1 to 29)
Blood samples were collected at pre-specified time points to determine the Tmax of MK-6194 in plasma.
Time frame: Day 1 (Predose and 12 hours postdose), Day 8, Day 15, and Day 29 (Predose and 12 hours postdose)
Geometric Mean Accumulation Ratio of AUC of MK-6194
Blood samples were collected at pre-specified time points to determine the geometric mean accumulation ratio of AUC of MK-6194. The accumulation ratio is defined as Day 29-43/ Day 1-15.
Time frame: Day 1 (Predose and 12 hours postdose), Day 8, Day 15, Day 29 (Predose and 12 hours postdose), Day 36, and Day 43
Geometric Mean Accumulation Ratio of Cmax of MK-6194
Blood samples were collected at pre-specified time points to determine the geometric mean accumulation ratio of Cmax of MK-6194. The accumulation ratio is defined as Day 29-43/ Day 1-15.
Time frame: Day 1 (Predose and 12 hours postdose), Day 8, Day 15, Day 29 (Predose and 12 hours postdose), Day 36, and Day 43
Fold Change From Baseline in Peak Regulatory T Cells (Tregs)
Blood samples were collected to determine the fold change from baseline (FCB) in peak Tregs. The peak Treg FCB was evaluated after the last dose of MK-6194 on Day 85 using natural-log transformed values with a linear model containing fixed effects.
Time frame: Baseline and Day 85
| Milestone | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) |
|---|---|---|---|---|
| Started | 18 | 6 | 36 | 12 |
| Completed | 16 | 5 | 32 | 11 |
| Not completed | 2 | 1 | 4 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 1 |
Blood samples were collected at pre-specified time points to determine the AUC1-15 of MK-6194 in plasma.
| day*ng/mL | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) |
|---|---|---|---|---|
| Area Under the Curve (AUC) From Days 1-15 (AUC1-15) of MK-6194 | — | 32.3 (13.9 to 75.1) | 59.6 (43.8 to 81.1) | — |
Blood samples were collected at pre-specified time points to determine the AUC29-43 of MK-6194 in plasma.
| day*ng/mL | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) |
|---|---|---|---|---|
| AUC From Days 29-43 (AUC29-43) of MK-6194 | — | 10.9 (4.13 to 28.7) | 56.7 (41.7 to 77.0) | 86.7 (47.0 to 160) |
Blood samples were collected at pre-specified time points to determine the Cmax of MK-6194 in plasma.
| ng/mL | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) |
|---|---|---|---|---|
| Peak Serum Concentration (Cmax) of MK-6194 (Day 1 to 29) | — | 13.2 (6.34 to 27.3) | 21.7 (16.8 to 27.9) | 20.0 (12.9 to 31.1) |
Blood samples were collected at pre-specified time points to determine the Ctrough of MK-6194 in plasma.
| ng/mL | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) |
|---|---|---|---|---|
| Minimum Serum Concentration (Ctrough) of MK-6194 (Day 1 to 29) | — | — | 0.210 (0.0141 to 3.13) | — |
Blood samples were collected at pre-specified time points to determine the Tmax of MK-6194 in plasma.
| day | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) |
|---|---|---|---|---|
| Time to Peak Serum Concentration (Tmax) of MK-6194 (Day 1 to 29) | — | 0.49 (0.48 to 0.49) | 0.49 (0.48 to 0.51) | 0.49 (0.42 to 0.50) |
Blood samples were collected at pre-specified time points to determine the geometric mean accumulation ratio of AUC of MK-6194. The accumulation ratio is defined as Day 29-43/ Day 1-15.
| Ratio | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) |
|---|---|---|---|---|
| Geometric Mean Accumulation Ratio of AUC of MK-6194 | — | 0.35 (0.13 to 0.96) | 0.98 (0.70 to 1.38) | — |
Blood samples were collected at pre-specified time points to determine the geometric mean accumulation ratio of Cmax of MK-6194. The accumulation ratio is defined as Day 29-43/ Day 1-15.
| Ratio | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) |
|---|---|---|---|---|
| Geometric Mean Accumulation Ratio of Cmax of MK-6194 | — | 0.84 (0.41 to 1.72) | 0.98 (0.79 to 1.20) | 1.35 (0.94 to 1.94) |
Blood samples were collected to determine the fold change from baseline (FCB) in peak Tregs. The peak Treg FCB was evaluated after the last dose of MK-6194 on Day 85 using natural-log transformed values with a linear model containing fixed effects.
| Fold change from baseline | Placebo | MK-6194 Low Dose of (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) |
|---|---|---|---|---|
| Fold Change From Baseline in Peak Regulatory T Cells (Tregs) | 1.15 (0.83 to 1.59) | 1.86 (0.95 to 3.66) | 1.69 (1.27 to 2.24) | 1.58 (1.05 to 2.38) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is presented.
| Participants | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) | MK-6194 Total |
|---|---|---|---|---|---|
| Number of Participants Who Experience One or More Adverse Events (AEs) | 13 | 6 | 30 | 9 | 45 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study intervention due to an AE is presented.
| Participants | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) | MK-6194 Total |
|---|---|---|---|---|---|
| Number of Participants Who Discontinue Study Intervention Due to an AE | 0 | 1 | 2 | 0 | 3 |
Collected over Up to approximately 169 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/18 (0%) | 0/18 (0%) | 13/18 (72.2%) |
| MK-6194 Low Dose (Panel A) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| MK-6194 High Dose (Panels B-E) | 0/36 (0%) | 2/36 (5.6%) | 30/36 (83.3%) |
| MK-6194 High Dose (Panel F) | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| MK-6194 Total | 0/54 (0%) | 2/54 (3.7%) | 45/54 (83.3%) |
| Event | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panels B-E) | MK-6194 High Dose (Panel F) | MK-6194 Total |
|---|---|---|---|---|---|
| Inguinal herniaGastrointestinal disorders | 0/18 | 0/6 | 1/36 | 0/12 | 1/54 |
| MalaiseGeneral disorders | 0/18 | 0/6 | 1/36 | 0/12 | 1/54 |
| Event | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panels B-E) | MK-6194 High Dose (Panel F) | MK-6194 Total |
|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 0/18 | 6/6 | 25/36 | 6/12 | 37/54 |
| Injection site indurationGeneral disorders | 0/18 | 3/6 | 8/36 | 0/12 | 11/54 |
| Injection site painGeneral disorders | 0/18 | 3/6 | 6/36 | 2/12 | 11/54 |
| NasopharyngitisInfections and infestations | 2/18 | 0/6 | 3/36 | 5/12 | 8/54 |
| NauseaGastrointestinal disorders | 0/18 | 2/6 | 0/36 | 0/12 | 2/54 |
| PruritusSkin and subcutaneous tissue disorders | 0/18 | 2/6 | 0/36 | 0/12 | 2/54 |
| EosinophiliaBlood and lymphatic system disorders | 0/18 | 1/6 | 7/36 | 3/12 | 11/54 |
| Injection site swellingGeneral disorders | 0/18 | 1/6 | 7/36 | 3/12 | 11/54 |
| HeadacheNervous system disorders | 4/18 | 1/6 | 4/36 | 0/12 | 5/54 |
| DiarrhoeaGastrointestinal disorders | 1/18 | 0/6 | 0/36 | 2/12 | 2/54 |
| Age, Continuous(Years) | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) | Total |
|---|---|---|---|---|---|
| Mean | 37.2 ± 11.0 | 46.5 ± 11.3 | 42.8 ± 16.8 | 42.0 ± 16.5 | 41.6 ± 15.0 |
| Sex: Female, Male(Participants) | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) | Total |
|---|---|---|---|---|---|
| Female | 5 | 2 | 18 | 5 | 30 |
| Male | 13 | 4 | 18 | 7 | 42 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 6 | 1 | 10 |
| Not Hispanic or Latino | 15 | 6 | 30 | 11 | 62 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | MK-6194 Low Dose (Panel A) | MK-6194 High Dose (Panel B-E) | MK-6194 High Dose (Panel F) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 2 | 0 | 3 | 2 | 7 |
| White | 14 | 6 | 31 | 10 | 61 |
| More than one race | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Aug 2022 to primary completion in May 2024, 21 months.
Results were first posted in Jun 2025, 1 year after primary completion.
Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 21 months is above that.
Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-6194